Pravastatin Actavis

New Zealand - English - Medsafe (Medicines Safety Authority)

Active ingredient:
Pravastatin sodium 20 mg;  
Available from:
Teva Pharma (New Zealand) Limited
INN (International Name):
Pravastatin sodium 20 mg
20 mg
Pharmaceutical form:
Active: Pravastatin sodium 20 mg   Excipient: Croscarmellose sodium Iron oxide yellow Lactose monohydrate Light magnesium oxide Magnesium stearate Microcelac 100 Povidone
Prescription type:
Manufactured by:
Biocon Limited
Therapeutic indications:
In hypercholesterolemic patients without clinically evident coronary heart disease, Pravastatin Actavis is indicated as an adjunct to diet to reduce the risk of fatal and non-fatal myocardial infarction, need for myocardial revascularisation procedures, and to improve survival by reducing cardiovascular deaths. Pravastatin Actavis is indicated for the reduction of elevated total and LDL-cholesterol levels in patients with primary hypercholesterolaemia when the response to diet and other nonpharmacological measures alone have been inadequate. Pravastatin Actavis is indicated as an adjunct to diet to slow the progressive course of atherosclerosis and reduce the incidence of clinical cardiovascular events in hypercholesterolaemic men under 75 years of age with coronary artery disease.
Product summary:
Package - Contents - Shelf Life: Blister pack, Alu-Alu blister pack with cardboard carton secondary packaging - 30 tablets - 36 months from date of manufacture stored at or below 25°C protect from light and moisture
Authorization number:
Authorization date:

Similar products

Search alerts related to this product

Share this information